Philippe G. Aftimos

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 115 publications

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

Journal: JCO precision oncology

Published: July 06, 2026

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 17, 2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Journal: Breast cancer research and treatment

Published: February 28, 2026

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open

Published: January 05, 2026

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

Journal: JAMA network open

Published: December 11, 2025

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal: Journal of the National Cancer Institute

Published: December 04, 2025

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

Journal: NPJ breast cancer

Published: December 03, 2025

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

Journal: ESMO open

Published: October 30, 2025

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.

Journal: ESMO open

Published: October 23, 2025

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 07, 2025

Showing 1-12 of 115

Last Updated: 09/26/2026